Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 8/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | ATP4A | P20648 | 2/20 | 0.33 |
| ▸ | ATP4B | P51164 | 2/20 | 0.33 |
| ▸ | TERT | O14746 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7107773 | 0.80 | ELANE (0.35) | KIF11KDM4EATP4AATP4BCYP3A4 | |
| SCHEMBL5037175 | 0.80 | ELANE (0.35) | KIF11KDM4EATP4AATP4BCYP3A4 | |
| SCHEMBL6529295 | 0.80 | ELANE (0.35) | KIF11KDM4EATP4AATP4BCYP3A4 | |
| SCHEMBL5746631 | 0.77 | ELANE (0.34) | KDM4EATP4AATP4BCYP3A4CYP2C9 | |
| SCHEMBL5041462 | 0.73 | ELANE (0.38) | KIF11KDM4EATP4AATP4BCYP3A4 | |
| SCHEMBL4972810 | 0.73 | ELANE (0.32) | — | |
| SCHEMBL4972816 | 0.73 | ELANE (0.32) | — | |
| SCHEMBL5745520 | 0.73 | ELANE (0.36) | GAA | |
| SCHEMBL5042223 | 0.73 | ATP4A (0.35) | KIF11KDM4EATP4AATP4BCYP3A4 | |
| SCHEMBL1814712 | 0.71 | CYP19A1 (0.45) | ATP4AATP4BCYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7314935-B2 | Tricyclic n-acyl compounds | ALTANA PHARMA AG (DE) | 2008-01-01 | — | — | US | disclosed |
| EP-1414821-B1 | TRICYCLIC EPOXIDES | ALTANA PHARMA AG (DE) | 2006-08-16 | — | — | EP | disclosed |
| US-6927292-B2 | Tricyclic epoxides | ALTANA PHARMA AG (DE) | 2005-08-09 | — | — | US | disclosed |
| US-20050148618-A1 | Tricyclic n-acyl compounds | ALTANA PHARMA AG (DE) | 2005-07-07 | — | — | US | disclosed |
| US-20040176597-A1 | Tricyclic epoxides | ALTANA PHARMA AG (DE) | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148618-A1 | Tricyclic n-acyl compounds | NAT1, AADAC, CYP1B1 | KIF11 3587/4885KDM4E 2624/4885GAA 229/4885 |
| US-20040176597-A1 | Tricyclic epoxides | VKORC1, CYP2E1, CYP1A2 | KIF11 4498/4885KDM4E 1288/4885GAA 798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.